Fig. 1From: Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASERDot plot showing the variations in the percentage of patients with juvenile idiopathic arthritis included in BIOBADASER annually who received their first biologic before age 16 since years 2000 to 2015Back to article page